Filing Flows › Protalix BioTherapeutics (PLX) › Capital expenditures
Protalix BioTherapeutics (PLX) capital expenditures by quarter
Protalix BioTherapeutics' capital expenditures were $761K in Q1 2026 (first quarter 2026), +89% from Q4 2025. Over the last 3 quarters it ranged from $403K (Q4 2025) to $761K (Q1 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q1 2026 | $761K | +89% | — |
| Q4 2025 | $403K | -5% | -5% |
| Q4 2024 | $425K | — | — |
Q1 2026 at a glance
Protalix BioTherapeutics, Q1 2026: revenue $33.8M (+234% year over year), operating margin 62.7%, net earnings $18.3M, operating cash flow $22.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Protalix BioTherapeutics' capital expenditures?
Protalix BioTherapeutics' capital expenditures were $761K in Q1 2026 (first quarter 2026), +89% from Q4 2025.
How has Protalix BioTherapeutics' capital expenditures changed?
Over the last 3 quarters it ranged from $403K (Q4 2025) to $761K (Q1 2026).
Q1 2026 results → · How Protalix BioTherapeutics makes money →